Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nyxoah Plans $70M+ IPO As It Starts IDE Trial For Neurostim Apnea Device

Executive Summary

Belgian firm will float on Euronext Brussels; ResMed and Cochlear among existing investors who will invest in at least 25% of shares.

You may also be interested in...



ResMed Jumps On Board As Nyxoah Raises €25m For Neurostim Apnea Device

The proceeds from the investment will enable Nyxoah to prepare for the IDE pivotal trial of the Genio system in the US, and accelerate market access and commercialization activities in Europe, Australia and New Zealand.

Infographic: Sleep Apnea Market To Reach Almost $10.3Bn By 2022

The market for devices to monitor and treat sleep apnea and its complications is set to grow by 7.3% annually in the next three years, with the US market expanding by 7.6% per year, according to the Meddevicetracker Dashboard.

Start-Up Spotlight: OrthoSon Targets Back Pain With Ultrasound, Injectable Hydrogel Combo

The Oxford University spin-off has raised over £3m so far to develop its minimally invasive disc nucleus replacement technology and plans a £10m series A.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel